Literature DB >> 15801961

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Koichi Kokame1, Yuko Nobe, Yoshihiro Kokubo, Akira Okayama, Toshiyuki Miyata.   

Abstract

A plasma metalloprotease, ADAMTS13, cleaves von Willebrand factor (VWF) multimers and downregulates their activity in platelet aggregation. Functional ADAMTS13 deficiency leads to the accumulation of hyperactive large VWF multimers, inducing a life-threatening disease, thrombotic thrombocytopenic purpura (TTP). Although measuring ADAMTS13 activity is important in TTP diagnosis, existing methods require time and skill. Here, we report a fluorescence resonance energy transfer (FRET) assay for ADAMTS13 activity. We developed a synthetic 73-amino-acid peptide, FRETS-VWF73. Cleavage of this substrate between two modified residues relieves the fluorescence quenching in the intact peptide. Incubation of FRETS-VWF73 with normal human plasma quantitatively increased fluorescence over time, while ADAMTS13-deficient plasma had no effect. Quantitative analysis could be achieved within a 1-h period using a 96-well format in commercial plate readers with common filters. The FRETS-VWF73 assay will be useful for the characterization of thrombotic microangiopathies like TTP and may clarify the importance of ADAMTS13 activity as a predictive marker for various thrombotic diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801961     DOI: 10.1111/j.1365-2141.2005.05420.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  152 in total

1.  Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Authors:  G B Fields
Journal:  Methods Mol Biol       Date:  2001

2.  Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

Authors:  Sumit Som; Cassandra C Deford; Mandi L Kaiser; Deirdra R Terrell; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George; Sara K Vesely
Journal:  Transfusion       Date:  2012-04-15       Impact factor: 3.157

3.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

4.  Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers.

Authors:  Svenja Lippok; Matthias Radtke; Tobias Obser; Lars Kleemeier; Reinhard Schneppenheim; Ulrich Budde; Roland R Netz; Joachim O Rädler
Journal:  Biophys J       Date:  2016-02-02       Impact factor: 4.033

5.  Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis.

Authors:  Frank C Vandy; Cathy Stabler; Anna M Eliassen; Angela E Hawley; Kenneth E Guire; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2013-04-01

6.  Predictive Ability of Preoperative PT-INR and Postoperative MCP1 for Post-hepatectomy Liver Failure.

Authors:  Sayaka Arisaka; Ryusei Matsuyama; Koki Goto; Yusuke Suwa; Ryutaro Mori; Daisuke Morioka; Masataka Taguri; Itaru Endo
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

7.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  Interaction of Shiga toxin with the A-domains and multimers of von Willebrand Factor.

Authors:  Nathan C Lo; Nancy A Turner; Miguel A Cruz; Joel Moake
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

9.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.